Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study

Jean-Louis Pujol, Jean Pierre Daurès, Aart Brutel de la Rivière, +10

JNCI Journal of the National Cancer Institute

Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.

M. Pérol, C. Chouaïd, B. Milleron, +7

Journal of Clinical Oncology

Advanced NsclcOncologyCancer ManagementPharmacologyPharmacotherapy +13

Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC).

Élisabeth Quoix, J.P. Oster, V. Westeel, +7

Journal of Clinical Oncology

Weekly PaclitaxelPharmacotherapyOverall SurvivalCarboplatin DoubletPre-clinical Pharmacology +16

New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen.

V. Westeel, Nevin Murray, Karen A. Gelmon, +12

Journal of Clinical Oncology

Long-term results of the French randomized trial comparing neoadjuvant chemotherapy followed by surgery versus surgery alone in resectable non-small cell lung cancer.

V. Westeel, B. Milleron, Élisabeth Quoix, +7

Journal of Clinical Oncology

Surgical OncologyCancer ManagementMultimodalityFrench Randomized TrialSurgery +16

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic

Nicolas Girard, Laurent Greillier, Gérard Zalcman, +13

Respiratory Medicine and Research

Clinical ManagementGlobal Health CrisisCovid-19 PandemicPatient SafetyThoracic Malignancies +4

[Respective influence of occupational and personal factors on respiratory function in dairy farmers].

Didier Choma, V. Westeel, A. Dubiez, +9

PubMed

Randomized phase IIb trial evaluating the therapeutic vaccine TG4010 (MVA-MUC1-IL2) as an adjunct to chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)

Rodryg Ramlau, V. Westeel, Zsolt Pápai, +7

Journal of Clinical Oncology

ImmunodeficienciesImmunologyImmunoeditingImmunotherapeuticsTherapeutic Vaccine Tg4010 +16

[Standards, options and recommendations for the management of locally advanced non small cell lung carcinoma].

É. Bardet, Denis Moro‐Sibilot, T. Le Chevalier, +30

PubMed